公开(公告)号：US09993494B2

公开(公告)日：2018-06-12

申请号：US14616690

申请日：2015-02-07

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： James Appleman ,  Peggy A. Thompson

IPC: A61K45/06 ,  A61K31/713 ,  C12Q1/68 ,  A61K31/155 ,  A61K31/16 ,  A61K31/357 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4418 ,  A61K31/496 ,  A61K31/519 ,  A61K31/706

CPC classification number: A61K31/713 ,  A61K31/155 ,  A61K31/16 ,  A61K31/357 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4418 ,  A61K31/496 ,  A61K31/519 ,  A61K31/706 ,  A61K45/06

Abstract: The present disclosure relates to compositions and methods for treating or preventing a fibrotic disorder or disease.

公开(公告)号：US09957277B2

公开(公告)日：2018-05-01

申请号：US15358761

申请日：2016-11-22

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Justin T. Ernst ,  Siegfried H. Reich ,  Paul A. Sprengeler ,  Chinh Viet Tran ,  Garrick Kenneth Packard ,  Alan X. Xiang ,  Christian Nilewski ,  Theo Michels

IPC: C07D491/00 ,  C07D491/048 ,  C07D307/93 ,  C07D333/78 ,  C07D491/153 ,  C07D491/16 ,  C07D491/20 ,  C07D498/14 ,  C07D519/00

CPC classification number: C07D491/048 ,  C07D307/93 ,  C07D333/78 ,  C07D491/153 ,  C07D491/16 ,  C07D491/20 ,  C07D498/14 ,  C07D519/00

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20170247692A1

公开(公告)日：2017-08-31

申请号：US15114277

申请日：2015-02-06

Applicant: EFFECTOR THERAPEUTICS, INC.

Inventor： James Appleman ,  Peggy A. Thompson ,  Vera Huang

IPC: C12N15/113 ,  G01N33/50

CPC classification number: C12N15/113 ,  C07K14/705 ,  C12N2310/14 ,  G01N33/5023 ,  G01N33/5058

Abstract: The present disclosure relates to compositions and methods for treating or preventing a neurological disorder.

公开(公告)号：US20170191136A1

公开(公告)日：2017-07-06

申请号：US15389822

申请日：2016-12-23

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Peggy A. Thompson ,  Wenqiong Joan Chen ,  James Appleman

IPC: C12Q1/68 ,  A61K31/506 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  A61K31/506 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/574 ,  C12Q2600/112 ,  C12Q2600/118

Abstract: The present disclosure relates to compositions and methods for identifying or diagnosing a human subject having or suspected of having a hyperproliferative disease and who would benefit from treatment with a MNK inhibitor.

公开(公告)号：US20160317536A1

公开(公告)日：2016-11-03

申请号：US15187854

申请日：2016-06-21

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Siegfried H. Reich ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. ERNST

IPC: A61K31/506 ,  A61K31/52 ,  A61K31/551 ,  A61K31/519

CPC classification number: A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/551 ,  C07D471/04 ,  C07D471/10 ,  C07D471/20 ,  C07D473/34 ,  C07D487/04 ,  C07D491/20 ,  C07D495/20 ,  C07D519/00

Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

Abstract translation: 或其立体异构体，互变异构体或其药学上可接受的盐，其中R1，R2，R3，R4a，R4b，R5，R6，R7，R8，W1，W2，Y和n如本文所定义。 还描述了式I化合物的药学上可接受的组合物以及利用式I化合物和式I化合物的药学上可接受的组合物作为Mnk抑制剂以及用于治疗诸如癌症的疾病的治疗剂的方法。

公开(公告)号：US20160303124A1

公开(公告)日：2016-10-20

申请号：US15130538

申请日：2016-04-15

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Kevin R. Webster ,  Vikas Goel

IPC: A61K31/506 ,  A61K31/713 ,  A61K45/06 ,  A61K39/395

Abstract: The present disclosure relates to the use MNK-specific inhibitors to inhibit immunosuppression components, such as immune checkpoint proteins PD-1, PD-L1, LAG3, and/or immunosuppressive cytokines, such as IL-10, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease.

Abstract translation: 本公开涉及使用MNK特异性抑制剂来抑制免疫抑制成分，例如免疫检查点蛋白质PD-1，PD-L1，LAG3和/或免疫抑制性细胞因子如IL-10，以便抑制或释放免疫 抑制某些疾病，如癌症和传染病。

公开(公告)号：US20150224132A1

公开(公告)日：2015-08-13

申请号：US14616690

申请日：2015-02-07

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： James Appleman ,  Peggy A. Thompson

IPC: A61K31/713 ,  A61K31/4418 ,  A61K31/496 ,  A61K31/4245 ,  A61K45/06 ,  A61K31/436 ,  A61K31/16 ,  A61K31/155 ,  A61K31/706 ,  A61K31/357 ,  A61K31/519

CPC classification number: A61K31/713 ,  A61K31/155 ,  A61K31/16 ,  A61K31/357 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4418 ,  A61K31/496 ,  A61K31/519 ,  A61K31/706 ,  A61K45/06

Abstract: The present disclosure relates to compositions and methods for treating or preventing a fibrotic disorder or disease.

Abstract translation: 本公开涉及用于治疗或预防纤维化病症或疾病的组合物和方法。